Showing results (351-360 of 618) with videos related to

Sort By:
Pageof 62
The Lancet. Haematology|June 7, 2016
Potentially avoidable hospital admissions in older patients with acute myeloid leukaemia in the USA: a retrospective analysisAreej El-Jawahri, Tanya Keenan, Gregory A Abel, et al.
Cancer Cell|February 15, 2014
SYK is a critical regulator of FLT3 in acute myeloid leukemiaAlexandre Puissant, Nina Fenouille, Gabriela Alexe, et al.
Blood|July 2, 2016
Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasmsDavid A Hinds, Kimberly E Barnholt, Ruben A Mesa, et al.
Blood Advances|January 15, 2026
Stratifying Survival: The Role of Social Determinants of Health on AML Outcomes by ELN 2022 CriteriaShai Shimony, Yating Wang, Angel M Cronin, et al.
Cancer|July 13, 2019
Outcomes for older adults with acute myeloid leukemia after an intensive care unit admissionSamuel D Slavin, Alyssa Fenech, Amanda L Jankowski, et al.
Blood Advances|September 18, 2024
Risk of bleeding in patients with essential thrombocythemia and extreme thrombocytosisRathnam K Venkat, Robert A Redd, Amyah C Harris, et al.
Annals of Hematology|April 3, 2023
Response and resistance to cladribine in patients with advanced systemic mastocytosis: a registry-based analysisJohannes Lübke, Nicole Naumann, Georgia Metzgeroth, et al.
American Journal of Hematology|May 29, 2015
KIT D816V and JAK2 V617F mutations are seen recurrently in hypereosinophilia of unknown significanceJuliana Schwaab, Roland Umbach, Georgia Metzgeroth, et al.
Nature Genetics|March 17, 2009
JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasmsAmy V Jones, Andrew Chase, Richard T Silver, et al.
Blood|April 21, 2017
Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markersMohamad Jawhar, Juliana Schwaab, Nicole Naumann, et al.
Pageof 62